Medistim

Regulatory Filings • Jan 20, 2017

Medistim establishes direct sales operations in Spain

Medistim establishes direct sales operations in Spain

(Oslo, 20th of January 2017) Medistim ASA (OSE: MEDI),

a Norwegian company that develops and commercializes

medical equipment for use in cardiac, vascular and

transplant surgery, announces that they are

establishing a subsidiary and sales force in Spain.

Medistim has terminated its distributor agreement in

Spain and established a new subsidiary, Medistim Spain

S.L. With two territory sales managers based in Madrid

and Barcelona, this new subsidiary will serve our end

customers directly with support from the Head Office

in Oslo.

Annually, around 7.000 coronary artery bypass surgery

(CABG) procedures and 8.000 vascular procedures are

performed throughout the 56 cardiac centers and 75

vascular centers in Spain. Medistim currently has an

installed base of 80 systems, most of them on the

VeriQ platform and older versions that only include

flow measurement and do not support the imaging

modality. Medistim now has great potential to upgrade

the installed base to the MiraQ platform, which

provides the combination of ultrasound imaging and

transit time flow measurement (TTFM) in one system.

Medistim's technology is used in upwards of 80% of all

coronary surgical procedures as the installed base is

primarily in cardiac centers. This also shows there is

an untapped potential in the vascular market where

only a small number of Medistim systems are installed.

Medistim has been successful with direct sales and

customer support through its other subsidiaries in the

United States, Germany, UK and Denmark and is well

prepared to create results with the new establishment

in Spain. The company already has a solid revenue base

from probes, which are consumables to the installed

base.

"We are very pleased with the fact that we have a

direct operation in Spain. This will allow us to take

the lead to ensure that the installed base is upgraded

to the MiraQ platform with the combined TTFM and

ultrasound imaging technology" says Medistim's

President and CEO, Kari E. Krogstad. "Through direct

representation we will ensure that the hospitals get

the best support and service. The timing is also

opportune with regards to the vascular potential that

we have in Spain and there is already substantial

interest among new potential customers. With this

endeavor we are showing that we are serious about

establishing flow measurement and ultrasound imaging

technology as the 'standard of care' in Spain, within

both coronary and vascular surgery. We are working to

achieve routine use of the MiraQ system for the

benefit of surgeons and their patients as well as the

healthcare system in general."

About Medistim

Medistim is a medtech company that develops and

distributes ultrasound based surgical guidance and

quality assessment devices. With headquarters in

Oslo, Norway, Medistim was established in 1984, and

has a track record of profitable growth over the past

>10 years. The company is a pioneer within its

segment, and continues to invest in new product

development. Medistim has wholly owned subsidiaries

with sales organizations in the USA, Germany, UK,

Denmark and Norway, in addition to about 50

distributors in Europe, Asia, Middle East, Africa and

South America.

For more information, visit the Medistim home page:

www.medistim.com or contact:

President and CEO, Kari E. Krogstad, Medistim ASA

Tel: + 47 918 38 110

E-mail: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA

Tel: + 47 906 59 940

E-mail: thomas.jakobsen@medistim.com

This information is disclosed under Norwegian law

(Verdipapirhandelloven §5-12).